We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
The Chimeric Adenovirus (Ad5/35) Expressing Engineered Spike Protein Confers Immunity against SARS-CoV-2 in Mice and Non-Human Primates.
- Authors
Shin, Seung-Phil; Shin, Kwang-Soo; Lee, Jeong-Mi; Jung, In-Kyung; Koo, Jimo; Lee, Seung-Woo; Park, Seowoo; Shin, Jieun; Park, Myunghwan; Park, Bongju; Oh, Hanseul; Koo, Bon-Sang; Hong, Jungjoo; Ryu, Choong-Min; Kim, Jae-Ouk; Oh, Taegwon; Kang, Chang-Yuil
- Abstract
Several COVID-19 platforms have been licensed across the world thus far, but vaccine platform research that can lead to effective antigen delivery is still ongoing. Here, we constructed AdCLD-CoV19 that could modulate humoral immunity by harboring SARS-CoV-2 antigens onto a chimeric adenovirus 5/35 platform that was effective in cellular immunity. By replacing the S1/S2 furin cleavage sequence of the SARS-CoV-2 Spike (S) protein mounted on AdCLD-CoV19 with the linker sequence, high antigen expression was confirmed in various cell lines. The high levels of antigen expression contributed to antigen-specific antibody activity in mice and non-human primates (NHPs) with a single vaccination of AdCLD-CoV19. Furthermore, the adenovirus-induced Th1 immune response was specifically raised for the S protein, and these immune responses protected the NHP against live viruses. While AdCLD-CoV19 maintained neutralizing antibody activity against various SARS-CoV-2 variants, it was reduced to single vaccination for β and ο variants, and the reduced neutralizing antibody activity was restored with booster shots. Hence, AdCLD-CoV19 can prevent SARS-CoV-2 with a single vaccination, and the new vaccine administration strategy that responds to various variants can maintain the efficacy of the vaccine.
- Subjects
PROTEIN engineering; SARS-CoV-2; BOOSTER vaccines; VACCINE effectiveness; CELLULAR immunity
- Publication
Vaccines, 2022, Vol 10, Issue 5, p712
- ISSN
2076-393X
- Publication type
Article
- DOI
10.3390/vaccines10050712